- Home
- PYPL vs IQV Comparison
PYPL vs IQV Comparison
Compare PYPL & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PYPL | IQV |
|---|---|---|
| Founded | 1998 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Business Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.8B | 43.1B |
| IPO Year | 2015 | 2013 |
Fundamental Metrics
Financial Performance| Metric | PYPL | IQV |
|---|---|---|
| Price | $53.41 | $269.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 30 | 16 |
| Target Price | $61.48 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 11.2M | 1.2M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | ★ 35.59 | 4.67 |
| EPS | 1.21 | ★ 1.61 |
| Revenue | ★ $33,172,000,000.00 | $9,739,000,000.00 |
| Revenue This Year | $4.78 | $6.77 |
| Revenue Next Year | $4.24 | $5.89 |
| P/E Ratio | ★ $44.67 | $167.50 |
| Revenue Growth | 4.32 | ★ 41.60 |
| 52 Week Low | $38.46 | $154.50 |
| 52 Week High | $79.22 | $271.80 |
Technical Indicators
Market Signals| Indicator | PYPL | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 43.56 | 67.94 |
| Support Level | $51.92 | $159.91 |
| Resistance Level | $59.09 | $271.80 |
| Average True Range (ATR) | 1.57 | 6.60 |
| MACD | -0.51 | -1.06 |
| Stochastic Oscillator | 28.22 | 86.48 |
Price Performance
Historical ComparisonAbout PYPL PayPal Holdings Inc.
PayPal was spun off from eBay in 2015 and provides electronic payment solutions to merchants and consumers, with a focus on online transactions. The company had 439 million active accounts at the end of 2025. The company also owns Venmo, a person-to-person payment platform.
About IQV IQVIA Holdings Inc.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.